HF-158K1 by HighField Biopharmaceuticals for Prostate Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Prostate Cancer.

Beckman coulter life sciences achieves industry-first with commercial release of anti-TRBC2 conjugated antibody for flow cytometry

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, continues to lead the way with first-to-market concepts to help laboratories achieve goals

January 9, 2024

Same-sex sexual behavior may be a common feature of primate reproduction, study suggests

Observations of a wild colony of macaques over three years show same-sex sexual behavior among males is widespread and may be beneficial.

July 10, 2023

Karuna pushes back KarXT data readouts; Vir, GSK end flu collaboration; Silence’s $10M milestone payment

Plus, news about Cogent and Indivior: Karuna delays some KarXT readouts: As the drugmaker awaits closing of its large exit to Bristol Myers Squibb and

February 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.